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Psoriatic arthritis
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Abstract

Objective To evaluate the efficacy and safety of
ixekizumab alone or with concomitant conventional
disease-modifying antirheumatic drugs (cDMARDs) versus
placebo in patients with active psoriatic arthritis (PsA) as
part of a SPIRIT-P1 subgroup analysis (NCT01695239).
Methods Patients were stratified by cDMARD use
(concomitant cDMARDs use (including methotrexate)
or none (past or naïve use)) and randomly assigned to
treatment groups (ixekizumab 80 mg every 4 weeks
(IXEQ4W) or every 2 weeks (IXEQ2W) or placebo). Efficacy
was evaluated versus placebo at week 24 by the American
College of Rheumatology criteria (ACR20/50/70), modified
total Sharp score and Health Assessment QuestionnaireDisability Index (HAQ-DI). Safety was assessed according
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Results Regardless of concomitant cDMARD usage,
please visit the journal online
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of disease activity and physical function in patients with
active PsA relative to placebo, when used with or without
concomitant cDMARD therapy.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that is often associated
with psoriasis and other extra-articular

Key messages
What is already known about this subject?
►► Patients with psoriatic arthritis are clinically

managed with biologic agents and concomitant
conventional disease-modifying antirheumatic
drugs (cDMARDs).
►► Limited evidence exists demonstrating the
efficacy of biologic agents when used alone or
with concomitant cDMARDs, and there is limited
treatment guidance currently available regarding
the use of combination therapy.

What does this study add?
►► This subset analysis of SPIRIT-P1 demonstrated

that ixekizumab, a high-affinity monoclonal
antibody that selectively targets interleukin (IL)17A, improved measures of disease activity and
physical function in patients with active psoriatic
arthritis at 24 weeks relative to placebo, regardless
of concomitant cDMARD use.

How might this impact on clinical practice?
►► The findings from this study offer clinicians

additional insights on the utility of employing an
anti-IL-17A targeting agent, as represented by
ixekizumab, either alone or with concomitant
cDMARD use, including methotrexate, in biologicnaïve patients with active psoriatic arthritis.
►► The evidence provided herein has clinical relevance
as the therapeutic options for the treatment of
psoriatic arthritis continue to expand and treatment
guidelines evolve.

manifestations including joint inflammation
(peripheral and/or axial) and structural joint
damage.1 Quality of life in patients with PsA
is poor and worse than the quality of life in
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83.5 (19.5)

5.6 (5.8)

20.6 (13.3)

84.8 (19.7)

6.1 (7.4)

19.5 (12.8)

Weight (kg),
mean (SD)

Time since
PsA diagnosis
(years), mean
(SD)

Tender joint
count (68
joints), mean
(SD)

IXEQ2W, n=63

21.2 (36.9)

1.19 (0.60)

18.9 (32.2)

HAQ-DI total
score, mean
(SD)
van der Heijde
mTSS, mean
(SD)
17.3 (32.7)

1.23 (0.55)

11.8 (7.6)

21.4 (15.1)

7.4 (7.4)

81.0 (16.7)

27 (42.9)

49.3 (12.8)

17 (28.6)

1.21 (0.60)

11.3 (8.1)

20.6 (13.4)

6.1 (7.6)

84.87 (20.1)

25 (42.4)

51.3 (12.8)

21 (38.4)

1.21 (0.53)

10.8 (7.9)

20.5 (13.8)

5.1 (5.3)

84.58 (20.0)

24 (42.1)

49.9 (10.3)

IXEQ4W, n=57

19.2 (35.2)

1.25 (0.57)

11.4 (6.0)

21.1 (15.6)

7.8 (7.8)

81.88 (15.8)

23 (43.4)

50.1 (12.7)

IXEQ2W, n=53

15.3 (21.6)

1.09 (0.62)

10.1 (6.4)

18.6 (13.4)

6.8 (5.8)

81.8 (19.6)

16 (43.2)

49.9 (12.1)

PBO, n=37

15.7 (23.9)

1.22 (0.56)

12.6 (9.4)

20.3 (14.4)

7.3 (7.3)

88.9 (28.0)

16 (41.0)

49.1 (10.4)

IXEQ4W, n=39

11.9 (21.4)

1.09 (0.59)

12.5 (6.7)

21.8 (12.4)

7.0 (9.1)

82.6 (18.8)

21 (52.5)

50.5 (12.4)

IXEQ2W, n=40

The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab combined with cDMARDs.
cDMARD, conventional disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg
ixekizumab once every 4 weeks; mTSS, modified total Sharp score; MTX, methotrexate; n, number of patients; PBO, placebo; PsA, psoriatic arthritis.

1.25 (0.54)

10.9 (7.7)

Swollen joint
count (66
joints), mean
(SD)

10.8 (7.4)

29 (42.6)

32 (46.4)

Male, n (%)

49.1 (10.0)

PBO, n=59

IXEQ4W, n=68

51.0 (12.5)

PBO, n=69

Age (years),
mean (SD)

MTX

cDMARD

None (cDMARD-naïve or past use at baseline)

Baseline demographics and disease characteristics of the patients according to concomitant cDMARD or MTX use at baseline subdivided by treatment group
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Concomitant
treatment

Table 1
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Psoriatic arthritis

Response Rate (%)

A)

MTX
cDMARD
naive or past use

ACR20
100
80

**

60

*

**

*** **

**

40
20
0

n

69

59

37

68

PBO

57

39

63

IXEQ4W

53

40

IXEQ2W

Response Rate (%)

B)
ACR50
100
80
60

***

*

40

*** ** ***

20
0

n

69

59

37

68

PBO

57

39

63

IXEQ4W

53

40

IXEQ2W

Response Rate (%)

C)
ACR70
100
80
60
40

*

20
0

n

69

59
PBO

37

68

**
57
IXEQ4W

39

*** *** ***
63

53

40

IXEQ2W

Figure 1 ACR response rates at 24 weeks in patients
treated with PBO, IXEQ4W or IXEQ2W alone or in
combination with cDMARDs or MTX. The proportions of
patients achieving ACR20 (A), ACR50 (B) and ACR70 (C)
are shown. The study was not designed to test equivalence
or non-inferiority of treatment with ixekizumab alone
versus treatment with ixekizumab in combination with
cDMARDs. ACR20/50/70, 20%/50%/70% American College
of Rheumatology response; cDMARD, conventional diseasemodifying antirheumatic drugs; PBO, placebo; IXEQ4W,
80 mg ixekizumab once every 4 weeks; IXEQ2W, 80 mg
ixekizumab once every 2 weeks; n, number of patients; MTX,
methotrexate. *P<0.05, **P<0.01, ***P<0.001, all versus PBO.

patients with psoriasis alone.2 Abundant evidence indicates that the proinflammatory cytokine interleukin (IL)17A promotes joint inflammation and damage in PsA.1
Ixekizumab is a high-affinity monoclonal antibody that
selectively targets IL-17A and has been demonstrated to
improve PsA disease activity and physical function, and
inhibit structural progression of joint damage in biologic-naïve patients with active PsA.3 4
Treatment of patients with PsA with biologics with
concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) is common, but no specific
Coates LC, et al. RMD Open 2017;0:e000567. doi:10.1136/rmdopen-2017-000567

recommendations have been released by the Group
for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) due to insufficient evidence.5 Prior
studies of tumour necrosis factor inhibitors (TNFi)6–14
and an IL-17A inhibitor15 16 indicate that clinical efficacy
is achieved with biologics alone or biologics with concomitant methotrexate (MTX), a commonly used cDMARD.
In addition, PsA registry studies report minimal or no
additional improvement in patients with PsA who have
been treated with TNFis and concomitant cDMARDs
versus TNFis alone.17–20 In the SPIRIT-P1 study, 64% of
patients used cDMARDs at baseline.3 Here, we evaluated
the efficacy and safety of ixekizumab relative to placebo
when used alone or with concomitant cDMARDs during
the double-blind treatment period of the SPIRIT-P1
study.
Materials and methods
Study design
We analysed efficacy, physical function and safety data
from the 24-week double-blind, active and placebo-controlled period of the SPIRIT-P1 trial of ixekizumab.3 At
study initiation, patients were randomised, and received
either ixekizumab 80 mg every 4 weeks (IXEQ4W), ixekizumab 80 mg every 2 weeks (IXEQ2W), adalimumab
40 mg every 2 weeks (ADA) or placebo, all administered
subcutaneously. ADA was the active reference arm, but
ADA results were not included in this report.3 In ixekizumab treatment groups, patients received an initial
160 mg dose of ixekizumab. Patients were stratified by
cDMARD usage (current use (must have been treated for
at least 12 weeks prior to baseline and on a stable dosage
for at least 8 weeks), past use (no current cDMARD
use, with past use occurring more than 8 weeks prior
to study baseline) or naïve to cDMARDs (no past use of
cDMARDs)) prior to randomisation. Patients who were
taking concomitant medications, including cDMARDs,
were required to remain on the same background treatment regimen, unless required to stop, modify or change
concomitant medication for safety reasons, through the
24-week double-blind treatment period, or if they were
designated an inadequate responder and required rescue
therapy at week 16.
Participants
Enrolled patients were biologic-naïve and fulfilled the
Classification Criteria for Psoriatic Arthritis21; had ≥3
of 68 tender joints and ≥3 of 66 swollen joints; had
either ≥1 PsA-related hand or foot erosion on centrally
read X-rays or C reactive protein >6 mg/L; and active
or documented personal history of plaque psoriasis. All
patients provided written informed consent. The study
was registered as SPIRIT-P1 on C
linicalTrials.
gov
(NCT01695239).
Efficacy, physical function and safety assessments
PsA disease activity was measured by the proportion of
patients achieving the American College of Rheumatology
3
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cDMARD
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cDMARD
Concomitant PBO,
treatment
n=58
mTSS LSM
0.44
change from (0.100)
baseline at
week 24 (SE)

None
(cDMARD-naïve or past use at
baseline)

MTX
IXEQ4W,
n=63

IXEQ2W,
n=60

PBO,
n=48

IXEQ4W,
n=52

IXEQ2W,
n=49

PBO,
n=35

IXEQ4W,
n=37

IXEQ2W,
n=37

0.11
(0.096)*

0.11
(0.098)*

0.52
(0.135)

0.13
(0.121)*

0.14
(0.114)*

0.57
(0.157)

0.25
(0.153)

0.03
(0.153)*

The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with
ixekizumab with concomitant cDMARDs.
*P<0.05 versus PBO.
cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W,
80 mg ixekizumab once every 4 weeks; LSM, least squares mean; mTSS, van der Heijde modified total Sharp score; MTX,
methotrexate; n, number of patients; PBO, placebo.
cDMARD

Change from Baseline,LSM

A)
0.0

n

69

PBO
59

MTX

36

64

cDMARD naive or past use
IXEQ4W
53

38

61

IXEQ2W
52

37

-0.2
-0.4

**

*
**

**

-0.6

***

***

-0.8

B)
Percentage of Patients
Achieving MCID

100
80

***

60

***

*

*

40
20
0

n

62

53

PBO

30

62

52

IXEQ4W

38

56

47

IXEQ2W

34

Figure 2 HAQ-DI change from baseline and proportion of
patients achieving MCID after 24 weeks in patients treated
with PBO, IXEQ4W or IXEQ2W alone or in combination
with cDMARDs or MTX. (A) LSM changes from baseline of
HAQ-DI. (B) Proportion of patients achieving MCID. The
study was not designed to test equivalence or non-inferiority
of ixekizumab alone versus treatment with ixekizumab
in combination with cDMARDs. cDMARD, conventional
disease-modifying antirheumatic drugs; HAQ-DI, Health
Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg
ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab
once every 4 weeks; LSM, least squares mean; MCID,
minimal clinically important difference; MTX, methotrexate;
n, number of patients; PBO, placebo. *P<0.05, **P<0.01,
***P<0.001, all versus PBO.

Index (HAQ-DI) at week 24; and also by calculation of
the proportion of patients achieving minimal clinically
important difference (MCID) in the HAQ-DI.24 25 Safety
was assessed by the proportion of patients experiencing
treatment-emergent adverse events (TEAE), serious
adverse events (AE) and discontinuations due to AE.
Statistical analyses
Efficacy analyses were conducted on the intent-to-treat
population, defined as all randomly assigned patients
and on subgroups defined by concomitant cDMARD
(MTX, ciclosporin, leflunomide or sulfasalazine) or
MTX usage. Analysis subgroups were defined as those
receiving ixekizumab with concomitant cDMARDs, ixekizumab with concomitant MTX or ixekizumab alone
(either cDMARD-naïve or past use). Subgroup analyses of
ACR20 response rate and mTSS assessments in patients
subdivided by concomitant cDMARD use were prespecified analyses, while all other analyses presented here were
post-hoc analyses. Safety analyses were conducted on
the safety population, defined as all randomly assigned
patients who received at least one dose of study medication, and grouped by the defined analysis subgroups.
Treatment by subgroup interaction was tested at the
significance level of 0.10 using either a logistic regression
model for categorical data or an analysis of covariance
(ANCOVA) model for continuous data, as appropriate.
Within each subgroup, Fisher’s exact test was used for
treatment comparisons of categorical endpoints and AE
data, and an ANCOVA model was used for comparisons
of mTSS and HAQ-DI data. All comparisons were relative to the placebo group. Missing values were imputed
by non-responder imputation for categorical endpoints,
linear extrapolation for mTSS change from baseline and
last observation carried forward for HAQ-DI data.

(ACR) 20, ACR50 and ACR70 responses at week 2422;
change from baseline in van der Heijde modified total
Sharp score (mTSS) at week 2423; change from baseline in the Health Assessment Questionnaire-Disability

Results
The SPIRIT-P1 patient population was previously
described by Mease and colleagues.3 In the patient population treated with concomitant cDMARDs at baseline,

4
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Table 2 Structural disease progression at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in
combination with cDMARD or MTX

Psoriatic arthritis

Concomitant
treatment

cDMARD

None (cDMARD-naïve or past
use at baseline)

MTX

PBO,
n=69

IXEQ4W,
n=68

Treatment-emergent
AE, n (%)

30 (43.5)

  Mild
  Moderate

IXEQ2W,
n=63

IXEQ4W,
n=57

IXEQ2W,
n=53

PBO,
n=37

IXEQ4W,
n=39

IXEQ2W,
n=39

42 (61.8)* 40 (63.5)* 27 (45.8)

36 (63.2)

34 (64.2)

20 (54.1)

29 (74.4)

27 (69.2)

15 (21.7)

28 (41.2)* 23 (36.5)

13 (22.0)

25 (43.9)*

18 (34.0)

12 (32.4)

15 (38.5)

18 (46.2)

13 (18.8)

13 (19.1)

12 (20.3)

10 (17.5)

13 (24.5)

8 (21.6)

11 (28.2)

7 (17.9)

14 (22.2)

PBO,
n=59

  Severe

2 (2.9)

1 (1.5)

3 (4.8)

2 (3.4)

1 (1.8)

3 (5.7)

0

3 (7.7)

2 (5.1)

Serious AE, n (%)
AE leading to
discontinuation, n (%)

2 (2.9)
2 (2.9)

3 (4.4)
1 (1.5)

4 (6.3)
4 (7.5)

1 (1.7)
2 (3.4)

2 (3.5)
1 (1.8)

0
4 (7.5)

0
0

3 (7.7)
1 (2.6)

3 (7.7)
0

The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab
combined with cDMARDs.
*P<0.05 versus PBO.
AE, adverse events; cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks;
IXEQ4W, 80 mg ixekizumab once every 4 weeks; MTX, methotrexate; n, number of patients; PBO, placebo.

83.8%–85.5% of patients were treated with MTX. Patient
demographics and characteristics were similar across
subgroups (table 1).
No interaction in treatment-by-cDMARD use was
observed in the study (P>0.1). Patients treated with either
IXEQ4W or IXEQ2W had significantly higher ACR20,
ACR50 and ACR70 response rates at 24 weeks compared
with placebo, regardless of concomitant cDMARD use
(figure 1A–C). IXEQ4W with concomitant MTX use had
significantly higher ACR20 response rates and numerically higher, but not statistically significant, ACR50 and
ACR70 response rates relative to placebo (figure 1). ACR
response rates for IXEQ2W with concomitant MTX use
were consistent with those reported relative to placebo
for IXEQ2W with concomitant cDMARD use.
Progression of structural damage, as measured by
change from baseline in mTSS at 24 weeks, was significantly less in patients treated with IXEQ4W or IXEQ2W
with concomitant cDMARD or MTX use and IXEQ2W
alone when compared with the placebo groups (table 2).
In patients treated with IXEQ4W alone, change from
baseline in mTSS at 24 weeks was numerically lower than
placebo (0.25 vs 0.57, respectively), but not statistically
significant.
Improvements in physical function, as assessed by
HAQ-DI, showed that patients treated with either
IXEQ4W or IXEQ2W had significantly greater improvement than placebo regardless of concomitant cDMARD
or MTX use (figure 2A). The proportion of patients who
reached a HAQ-DI MCID (improvement in HAQ-DI
total score ≥0.35 from baseline) was significantly higher
than placebo for IXEQ4W alone and IXEQ2W, regardless of concomitant cDMARD or MTX use (figure 2B).
Although not statistically significant, treatment with
IXEQ4W with concomitant cDMARDs or MTX use had a
numerically higher proportion of patients who achieved
HAQ-DI MCID relative to placebo.

Discussion
In biologic-naïve patients with PsA, ixekizumab demonstrated efficacy relative to placebo, regardless of concomitant cDMARD use. Improvements were observed relative to placebo in disease activity, inhibition of structural
progression of disease and physical function in patients
treated with ixekizumab, regardless of concomitant
cDMARD use. Furthermore, the overall safety profile was
consistent with previous ixekizumab reports in patients
with psoriasis and PsA across treatment subgroups.3 26 27
Reports from PsA randomised controlled trials (RCTs)
for TNFis6–14 and an IL-17A inhibitor15 16 support our
results. All of these studies, including our results from
patients treated with ixekizumab, indicate clinical efficacy with biologics relative to placebo, regardless of
concomitant cDMARD use. In addition, results directly
comparing the efficacy of biologics alone with biologics
with concomitant cDMARD use are available from analyses of PsA registries, which also support the results we
observed in patients treated with ixekizumab. Studies of
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Overall, a numerically higher proportion of patients
who received IXEQ4W or IXEQ2W experienced at
least one TEAE when compared with patients receiving
placebo, regardless of concomitant cDMARD or MTX use
(table 3). In the groups with significantly higher frequencies of TEAEs reported, injection site reactions were the
most frequently reported TEAEs (IXEQ4W+cDMARD:
11.8%, n=8; IXEQ2W+cDMARD: 12.7%, n=8), but this is
consistent with previous SPIRIT-P1 reports for the overall
treatment groups.3 Mild TEAEs were significantly higher
versus placebo for IXEQ4W with concomitant cDMARD
or MTX use. The incidence of moderate TEAEs, severe
TEAEs, serious TEAEs and TEAEs leading to discontinuation was similar versus placebo across all treatment
groups, regardless of concomitant cDMARD or MTX use.

RMD Open: first published as 10.1136/rmdopen-2017-000567 on 22 December 2017. Downloaded from http://rmdopen.bmj.com/ on 5 June 2018 by guest. Protected by copyright.

Table 3 Safety overview after 24 weeks according to concomitant cDMARD or MTX use at baseline, subdivided by treatment

RMD Open
placebo, regardless of concomitant cDMARD use. The
safety profile of ixekizumab with or without concomitant cDMARD use is consistent with previous reports in
patients with PsA and psoriasis.3 26 27
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